Biotech Values

[genisi]

ZGEN
It is also my understanding that Recothrom will need another phase III study vs an available hemostatic agent in order to be approved by the EMEA. OMRI never made a big deal of Evithrom, Evicel was selling much better and the fibrin patch was meant to be the next driver. One point I've mentioned at the SI board is that the EU thrombin market is much smaller (about one sixth of the US). I asked Tuck if ZGEN would receive a double-digit royalties on ex-US sales of Recothrom as well, but he didn't know. Do you?